ImmunityBio’s $100 Million War Chest Meets a Storm of Lawsuits and Data Doubts

ImmunityBio's Q1 ANKTIVA sales surge 168% to $44.2M, but stock falls on FDA warning, shareholder lawsuits, and mixed clinical data. New $100M funding boosts runway.

ImmunityBio is living a tale of two realities. The biotech’s first-quarter sales of its cancer drug ANKTIVA have nearly tripled, and it has locked down $100 million in fresh funding to fuel a global push. Yet the stock is trading near $7.44, battered by a regulatory rebuke, a wave of shareholder lawsuits, and clinical data that left more questions than answers.

The company’s cash position stands at roughly $381 million, giving it ample runway. Of the new financing, $75 million is structured as non-dilutive capital—meaning existing shareholders’ stakes remain untouched—sourced from an existing agreement with Oberland Capital. That partner’s total commitment now reaches $375 million. An additional $25 million in debt was converted into roughly 4.6 million new shares, chipping away at a $505 million note that matured at the end of 2024.

A Record Quarter, but a Bruised Stock

The commercial engine is humming. Preliminary product revenue for ANKTIVA hit $44.2 million in the first quarter of 2026, a 168% jump from a year earlier and a 15% sequential gain over the fourth quarter of 2025. The drug is now approved or authorized in the U.S., the U.K., the European Union, Macau, and Saudi Arabia, with a recent MENA-region partnership targeting bladder and lung cancer.

But the market fixated on the negative. On April 24, the U.S. Food and Drug Administration sent a warning letter over “misleading advertising,” and the stock promptly shed about 9%. Days later, a data update from the Phase 2 QUILT-3.078 study in glioblastoma—one of the most aggressive brain cancers—sent shares down another 8.4% on Friday, with an intraday drop as deep as 12%. The median overall survival had not yet reached an endpoint, a result that can be clinically positive but often spooks investors in high-risk oncology.

Legal Storm Clouds Gather

The regulatory headache is now compounded by legal action. Multiple law firms, including Faruqi & Faruqi and Bronstein, Gewirtz & Grossman, have filed class-action suits alleging that CEO Patrick Soon-Shiong and management overstated ANKTIVA’s clinical capabilities. The class period covers investors who bought shares between January 19 and March 24, 2026, with a lead plaintiff deadline of May 26.

Japan Speculation Adds Fuel to the Fire

Adding a layer of intrigue, traders have latched onto a Japan trip by Soon-Shiong, spinning rumors of a potential multibillion-dollar deal with a Japanese partner. Speculation has pegged a possible transaction at up to $10 billion, tied to Japan’s accelerated approval program for innovative therapies. The company has offered no confirmation, but the chatter is enough to keep trading volumes elevated.

Pipeline Progress and What’s Next

Amid the noise, the pipeline is advancing. The pivotal QUILT-2.005 study for BCG-naive bladder cancer patients is fully enrolled, and an independent data safety committee has confirmed the trial has sufficient power to detect clinical differences. A supplemental FDA filing is planned for later this year. Meanwhile, ANKTIVA’s U.S. insurance coverage now reaches more than 100 million lives.

Analysts remain broadly bullish, with a consensus “Buy” rating and a price target of $14.80—nearly double the current level. Whether that gap narrows depends on how the lawsuits unfold and whether the FDA takes further action. Final first-quarter results are due in May, and they will be the next major test of whether commercial momentum can overcome the legal and regulatory headwinds.